Revolution Medicines
As of the edition of 20 October 2026, Revolution Medicines runs 9 drugs, 1 of them marketed; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- EQRx, Inc.: acquired in 2023; successor Revolution Medicines, Inc.
- EQRx International, Inc.: acquired in 2023; successor Revolution Medicines, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 6 |
| Stopped | 2 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Aumolertinib | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Revolution Medicines needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 14 trials led
- Digestive system: 10 trials led
- Lungs and airways: 10 trials led